SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

InfuSystem Holdings, Inc. (INFU) News

Follow InfuSystem Holdings, Inc. (INFU) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol INFU Asset equity Sector Markets 90 days 10 Last 14.38 Updated Nov 05, 2026, 11:48 AM UTC Open live news feed Open INFU chart & news
M InfuSystem Beats Q3 Profit Estimates on Oncology, Wound Care Growth InfuSystem reported Q3 profit above estimates, citing growth in oncology and wound care. EQUITY | Nov 05, 2026, 11:48 AM UTC M InfuSystem Q3 Net Income Rises 40% to $3.16 Million EARNINGS | Nov 05, 2026, 11:38 AM UTC L InfuSystem Holdings Reports Q3 EPS of $0.15 EARNINGS | Nov 05, 2026, 11:32 AM UTC L InfuSystem Holdings Reports Q3 Operating Income of $4.746 Million EARNINGS | Nov 05, 2026, 11:32 AM UTC M InfuSystem Holdings Reports Q3 Revenue of $37.589 Million EQUITY | Nov 05, 2026, 11:32 AM UTC M InfuSystem Announces Third-Quarter 2026 Financial Results InfuSystem announced its third-quarter 2026 financial results. An investor conference call is scheduled for November 10, 2026, at 9:00 a.m. Eastern Time. EQUITY | Nov 05, 2026, 11:31 AM UTC M InfuSystem Reports Q3 Gross Profit of $21.727 Million EQUITY | Nov 05, 2026, 11:30 AM UTC M InfuSystem Holdings Reports Q3 Pretax Profit of $4.544 Million EQUITY | Nov 05, 2026, 11:30 AM UTC M InfuSystem Postpones Q3 2026 Results, Reviews $4.2 Million in ERP Costs InfuSystem said it postponed its third-quarter 2026 results release while completing reporting and reviewing the accounting treatment of $4.2 million in ERP implementation costs. EQUITY | Nov 03, 2026, 01:15 PM UTC M Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7% EQUITY | Oct 06, 2026, 07:52 AM UTC